MedTrace Logo

Clinical Trial of Naoqingzhiming Tablets in Healthy Chinese Subjects

NCT04902534 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-05-26

No results posted yet for this study

Summary

A single-center, randomized, double-blind, placebo-controlled, dose escalation safety, tolerability, and pharmacokinetic phase I clinical study of Naoqingzhiming Tablets in Chinese healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Naoqingzhiming Tablets (contains echinacoside 180mg)

Single dose escalation and multiple dose escalation

DRUG

placebo of Naoqingzhiming Tablets (without echinacoside)

Single dose escalation and multiple dose escalation

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Principal Investigators

  • Yu Cao, Doctor · The Affiliated Hospital of Qingdao University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2021-05-30
Completion
2021-06-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902534 on ClinicalTrials.gov